const ktData = {
    title: 'Indications',
    subTitle: 'For KEYTRUDA® (pembrolizumab)',
    cancers: {
        ADVANCED_MELANOMA_OR_ADJUVANT_THERAPY_FOR_MELANOMA: {
            title: 'Advanced Melanoma or Adjuvant Therapy for Melanoma',
            list: [
                'KEYTRUDA is indicated for the treatment of patients with unresectable or metastatic melanoma.',
                'KEYTRUDA is indicated for the adjuvant treatment of patients with melanoma with involvement of lymph node(s) following complete resection.'
            ]
        },
        ADVANCED_NON_SMALL_CELL_LUNG_CANCER: {
            title: 'Advanced Non⁠–⁠Small Cell Lung Cancer (NSCLC)',
            list: [
                'KEYTRUDA, in combination with pemetrexed and platinum chemotherapy, is indicated for the first-line treatment of patients with metastatic  nonsquamous non⁠–⁠small cell lung cancer (NSCLC), with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK)    genomic tumor aberrations.',
                'KEYTRUDA, in combination with carboplatin and either paclitaxel or paclitaxel protein‑bound, is indicated for the first‑line treatment of  patients with metastatic squamous non⁠–⁠small cell lung cancer (NSCLC).',
                'KEYTRUDA, as a single agent, is indicated for the first-line treatment of patients with non⁠–⁠small cell lung cancer (NSCLC) expressing programmed death ligand 1 (PD⁠-⁠L1) [tumor proportion score (TPS) ≥1%] as determined by an FDA-approved test, with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumor aberrations, and is',
            ],
            subList: [
                'stage III where patients are not candidates for surgical resection or definitive chemoradiation, or',
                'metastatic.'
            ]
        }
    }
}

module.exports = ktData;